SCHEMBL2011883

SCHEMBL2011883

NCCc1ccc(C(N)(CN)c2ccccc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 8/20 0.58
HTR2A P28223 2/20 0.58
CYP2A6 P11509 2/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
LOXL2 Q9Y4K0 1/20 0.58
MAOB P27338 3/20 0.47
HTR6 P50406 1/20 0.47
CYP1A2 P05177 1/20 0.43
MAOA P21397 1/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HTR1A P08908 1/20 0.43
ADRA2A P08913 1/20 0.43
SLC6A2 P23975 1/20 0.43
CYP2C19 P33261 1/20 0.43
HTR3A P46098 1/20 0.43
BACE1 P56817 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6574459 0.85 HTR2A (0.54) TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2
SCHEMBL150158 0.82 TAAR1 (0.56) TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2
SCHEMBL27648862 0.80 TAAR1 (0.54) TAAR1LOXL2ALDH1A1SLC6A2
SCHEMBL7523537 0.80 TAAR1 (0.54) TAAR1LOXL2ALDH1A1SLC6A2
Hydrochloric Acid SCHEMBL29030881 0.80 TAAR1 (0.54) TAAR1HTR2ASMN1; SMN2LOXL2MAOB
Ammonia Solution, Strong SCHEMBL7564407 0.80 TAAR1 (0.54) TAAR1LOXL2ALDH1A1SLC6A2
SCHEMBL6910953 0.80 TAAR1 (0.58) TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2
Lithium Ion SCHEMBL10332441 0.78 TAAR1 (0.52) TAAR1LOXL2ALDH1A1SLC6A2
SCHEMBL11666325 0.78 TAAR1 (0.50) TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2
SCHEMBL2013028 0.77 TAAR1 (0.48) TAAR1HTR2ACYP2A6SMN1; SMN2LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964730-B2 Amino-substituted ethylamino β2 adrenergic receptor agonists THERAVANCE, INC. (US) 2011-06-21 US disclosed
US-20090111850-A1 Amino-Substituted Ethylamino Beta2 Adrenergic Receptor Agonists THERAVANCE BIOPHARMA R&D IP, LLC 2009-04-30 US disclosed
CN-100465158-C Amino-substituted ethylamino beta2-adrenergic receptor agonists THERAVANCE INC (US) 2009-03-04 CN disclosed
CN-1856465-A Amino-substituted ethylamino beta2-adrenergic receptor agonists THERAVANCE INC (US) 2006-11-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111850-A1 Amino-Substituted Ethylamino Beta2 Adrenergic Receptor Agonists ADRB2, ADRB1, ADRA2A TAAR1 60/4885HTR2A 66/4885CYP2A6 1198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.